On the interaction of adjuvant radiotherapy and tamoxifen treatment for breast cancer;Zur interaktion von strahlentherapie und tamoxifen beim mammakarzinom

Strahlentherapie und Onkologie

Volumn 183, Issue 10, 2007, Pages 535-544

  Hoeller, Ulrike ^a   Borgmann, Kerstin ^b   Feyer, Petra ^a,d   Souchon, Rainer ^c,d  

^a VIVANTES KLINIKUM NEUKÖLLN   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c Allgemeines Krankenhaus Hagen

^d DEGRO ^*

Author keywords

Breast cancer; Fibrosis; Radiotherapy; Tamoxifen

Indexed keywords

ESTROGEN; GROWTH FACTOR RECEPTOR; TAMOXIFEN;

BREAST CANCER; CANCER CONTROL; CLINICAL STUDY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFIDENCE INTERVAL; FOLLOW UP; HAZARD RATIO; HUMAN; LUNG FIBROSIS; MASTECTOMY; NONHUMAN; PNEUMONIA; RADIATION SAFETY; RADIODIAGNOSIS; RECURRENCE RISK; REVIEW; TUMOR CELL;

AGE FACTORS; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; COMBINED MODALITY THERAPY; DATA INTERPRETATION, STATISTICAL; FEMALE; HUMANS; LUNG; LUNG DISEASES; MASTECTOMY; MIDDLE AGED; NEOPLASMS, EXPERIMENTAL; PROSPECTIVE STUDIES; PULMONARY FIBROSIS; RADIOTHERAPY; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RISK FACTORS; TAMOXIFEN; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 34748905968     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-007-1710-5     Document Type: Review

References (77)

1. Ahn PH, Vu HT, Lannin D, et al. Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates. J Clin Oncol 2005;23:17-23.
2. Albain KS, Green SR, Ravdin P. Adjuvant chemotherapy for primary breast cancer should be sequential instead of concurrent: initial results from Intergroup trial 0100. Proc Am Soc Clin Oncol 2002;21:37a.
3. Andreassen CN. Can risk of radiotherapy-induced normal tissue complications be predicted from genetic profiles? Acta Oncol 2005;44:801-15.
4. Azria D, Gourgou S, Sozzi WJ, et al. Concomitant use of tamoxifen with radiotherapy enhances subcutaneous breast fibrosis in hypersensitive patients. Br J Cancer 2004;91:1251-60.
5. Azria D, Pelegrin A, Dubois JB, et al. Radiation therapy and tamoxifen: concurrent or sequential? It's no longer the question! J Clin Oncol 2005;23:4239-41, author reply 4241-2.
6. Bartelink H, Horiot JC, Poortmans P, et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 2001;345:1378-87.
7. Bartelink H, Rubens RD, van der Schueren E, et al. Hormonal therapy prolongs survival in irradiated locally advanced breast cancer: a European Organization for Research and Treatment of Cancer randomized phase III trial. J Clin Oncol 1997;15:207-15.
8. Bentzen SM. Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nat Rev Cancer 2006;6:702-13.
9. Bentzen SM, Skoczylas JZ, Overgaard M, et al. Radiotherapy-related lung fibrosis enhanced by tamoxifen. J Natl Cancer Inst 1996;88:918-22.
10. Bentzen SM, Yarnold JR. Sequential or concurrent tamoxifen and radiotherapy: to see or not to see - that is the question! J Clin Oncol 2005;23:6266-7, author reply 6267.
11. Böhning K, Busch M, Rave-Fränk M, et al. Effect of tamoxifen and estrogen treatment on the radiosensitivity of MCF-7 breast cancer cells. Onkologie 1996;19:163-9.
12. Brandt S, Kopp A, Grage B, et al. Effects of tamoxifen on transcriptional level of transforming growth factor beta (TGF-beta) isoforms 1 and 2 in tumor tissue during primary treatment of patients with breast cancer. Anticancer Res 2003;23:223-9.
13. Burger AM, Zhang X, Seth A. Detection of novel genes that are up-regulated (Di12) or down-regulated (T1A12) with disease progression in breast cancer. Eur J Cancer Prev 1998;7:Suppl 1:S29-35.
14. Butta A, MacLennan K, Flanders KC, et al. Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res 1992;52:4261-4.
15. Cariou S, Donovan JC, Flanagan WM, et al. Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc Natl Acad Sci U S A 2000;97:9042-6.
16. Chen H, Tritton TR, Kenny N, et al. Tamoxifen induces TGF-beta 1 activity and apoptosis of human MCF-7 breast cancer cells in vitro. J Cell Biochem 1996;61:9-17.
17. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;366:2087-106.
18. Colletta AA, Wakefield LM, Howell FV, et al. Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. Br J Cancer 1990;62:405-9.
19. Dalberg K, Johansson H, Johansson U, et al. A randomized trial of long term adjuvant tamoxifen plus postoperative radiation therapy versus radiation therapy alone for patients with early stage breast carcinoma treated with breast-conserving surgery. Stockholm Breast Cancer Study Group. Cancer 1998;82:2204-11.
20. Dörr W, Bertmann S, Herrmann T. Radiation induced lung reactions in breast cancer therapy. Modulating factors and consequential effects. Strahlenther Onkol 2005;181:567-73.
21. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
22. Ellis PA, Saccani-Jotti G, Clarke R, et al. Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer. Int J Cancer 1997;72:608-13.
23. Fagundes MA, Fagundes HM, Brito CS, et al. Breast-conserving surgery and definitive radiation: a comparison between quadrantectomy and local excision with special focus on local-regional control and cosmesis. Int J Radiat Oncol Biol Phys 1993;27:553-60.
24. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 2000;355:1757-70.
25. Fehlauer F, Tribius S, Alberti W, et al. Late effects and cosmetic results of conventional versus hypofractionated irradiation in breast-conserving therapy. Strahlenther Onkol 2005;181:625-31.
26. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989;320:479-84.
27. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996; 88:1529-42.
28. Fowble B, Fein DA, Hanlon AL, et al. The impact of tamoxifen on breast recurrence, cosmesis, complications, and survival in estrogen receptor-positive early-stage breast cancer. Int J Radiat Oncol Biol Phys 1996;35:669-77.
29. Harris EE, Christensen VJ, Hwang WT, et al. Impact of concurrent versus sequential tamoxifen with radiation therapy in early-stage breast cancer patients undergoing breast conservation treatment. J Clin Oncol 2005;23:11-6.
30. Herskind C, Bamberg M, Rodemann HP. The role of cytokines in the development of normal-tissue reactions after radiotherapy. Strahlenther Onkol 1998;174:Suppl 3:12-5.
31. Herskind C, Johansen J, Bentzen SM, et al. Fibroblast differentiation in subcutaneous fibrosis after postmastectomy radiotherapy. Acta Oncol 2000;39:383-8.
32. Hoeller U, Borgmann K, Bonacker M, et al. Individual radiosensitivity measured with lymphocytes may be used to predict the risk of fibrosis after radiotherapy for breast cancer. Radiother Oncol 2003;69:137-44.
33. Hoeller U, Kuhlmey A, Bajrovic A, et al. Cosmesis from the patient's and the doctor's view. Int J Radiat Oncol Biol Phys 2003;57:345-54.
34. Holli K, Pitkanen M, Jarvenpaa R, et al. Early skin and lung reactions in breast cancer patients after radiotherapy: prospective study. Radiother Oncol 2002;64:163-9.
35. Huang EY, Wang CJ, Chen HC, et al. Multivariate analysis of pulmonary fibrosis after electron beam irradiation for postmastectomy chest wall and regional lymphatics: evidence for non-dosimetric factors. Radiother Oncol 2000;57:91-6.
36. Kantorowitz DA, Thompson HJ, Furmanski P. Effect of conjoint administration of tamoxifen and high-dose radiation on the development of mammary carcinoma. Int J Radiat Oncol Biol Phys 1993;26:89-94.
37. Kleeberg U. Tamoxifen nach und nicht simultan zur Strahlentherapie. Strahlenther Onkol 2006;182:195.
38. Koc M, Polat P, Suma S. Effects of tamoxifen on pulmonary fibrosis after cobalt-60 radiotherapy in breast cancer patients. Radiother Oncol 2002;64:171-5.
39. Lemon HM, Kumar PF, Peterson C, et al. Inhibition of radiogenic mammary carcinoma in rats by estriol or tamoxifen. Cancer 1989;63:1685-92.
40. Lind PA, Marks LB, Hardenbergh PH, et al. Technical factors associated with radiation pneumonitis after local +/- regional radiation therapy for breast cancer. Int J Radiat Oncol Biol Phys 2002;52:137-43.
41. Lind PA, Rosfors S, Wennberg B, et al. Pulmonary function following adjuvant chemotherapy and radiotherapy for breast cancer and the issue of three-dimensional treatment planning. Radiother Oncol 1998;49:245-54.
42. Mabuchi S, Ohmichi M, Kimura A, et al. Tamoxifen inhibits cell proliferation via mitogen-activated protein kinase cascades in human ovarian cancer cell lines in a manner not dependent on the expression of estrogen receptor or the sensitivity to cisplatin. Endocrinology 2004;145:1302-13.
43. Mandlekar S, Kong AN. Mechanisms of tamoxifen-induced apoptosis. Apoptosis 2001;6:469-77.
44. Marinus J, Niel CG, de Bie RA, et al. Measuring radiation fibrosis: the interobserver reliability of two methods of determining the degree of radiation fibrosis. Int J Radiat Oncol Biol Phys 2000;47:1209-17.
45. Martin M, Lefaix J-L, Delanian SD. TGF-β1 and radiation fibrosis: a master switch and a specific therapeutic target? Int J Radiat Oncol Biol Phys 2000;47:277-90.
46. Morena AM, Oshima CT, Gebrim LH, et al. Early nuclear alterations and immunohistochemical expression of Ki-67, Erb-B2, vascular endothelial growth factor (VEGF), transforming growth factor (TGF-beta1) and integrine-linked kinase (ILK) two days after tamoxifen in breast carcinoma. Neoplasma 2004;51:481-6.
47. Newton C, Schlatterer K, Stalla G, et al. Pharmacological enhancement of radiosurgery response: studies on an in vitro model system. J Radiosurg 1998;1:51-6.
48. O'Sullivan B, Levin W. Late radiation-related fibrosis: pathogenesis, manifestations, and current management. Semin Radiat Oncol 2003;13:274-89.
49. Osborne CK, Boldt DH, Clark GM, et al. Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase. Cancer Res 1983;43:3583-5.
50. Osborne CK, Shou J, Massarweh S, et al. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 2005;11:865s-70s.
51. Paulsen GH, Strickert T, Marthinsen AB, et al. Changes in radiation sensitivity and steroid receptor content induced by hormonal agents and ionizing radiation in breast cancer cells in vitro. Acta Oncol 1996;35:1011-9.
52. Perry RR, Kang Y, Greaves B. Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells. Ann Surg Oncol 1995;2:238-45.
53. Pierce LJ, Hutchins LF, Green SR, et al. Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer. J Clin Oncol 2005;23:24-9.
54. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group. J Natl Cancer Inst 1996;88:1543-9.
55. Rodemann HP. [The role of proto-oncogene expression in cellular radiosensitivity and radioresistance.] Strahlenther Onkol 1994;170:725-7.
56. Rodemann HP, Bamberg M. Cellular basis of radiation-induced fibrosis. Radiother Oncol 1995;35:83-90.
57. Rodemann HP, Binder A, Burger A, et al. The underlying cellular mechanism of fibrosis. Kidney Int Suppl 1996;54:S32-6.
58. Rube CE, Rodemann HP, Rube CR. Die Bedeutung von Zytokinen für die radiogene Lungenreaktion. Strahlenther Onkol 2004;180:541-9.
59. Rutqvist LE, Cedermark B, Glas U, et al. Radiotherapy, chemotherapy, and tamoxifen as adjuncts to surgery in early breast cancer: a summary of three randomized trials. Int J Radiat Oncol Biol Phys 1989;16:629-39.
60. Rutqvist LE, Cedermark B, Glas U, et al. Randomized trial of adjuvant tamoxifen combined with postoperative radiation therapy or adjuvant chemotherapy in postmenopausal breast cancer. Cancer 1990;66:89-96.
61. Rutqvist LE, Cedermark B, Glas U, et al. Randomized trial of adjuvant tamoxifen in node negative postmenopausal breast cancer. Stockholm Breast Cancer Study Group. Acta Oncol 1992;31:265-70.
62. Sarkaria JN, Miller EM, Parker CJ, et al. 4-hydroxytamoxifen, an active metabolite of tamoxifen, does not alter the radiation sensitivity of MCF-7 breast carcinoma cells irradiated in vitro. Breast Cancer Res Treat 1994;30:159-65.
63. Sauer G, Strnad V, Kurzeder C, et al. Partial breast irradiation after breast-conserving surgery. Strahlenther Onkol 2005;181:1-8.
64. Sauer R, Budach W, Dunst J, et al. Radiotherapie des Mammakarzinoms. Strahlenther Onkol 2006;182:1-28.
65. Schiff R, Massarweh S, Shou J, et al. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res 2003;9:447S-54S.
66. Schmidberger H, Hermann RM, Hess CF, et al. Interactions between radiation and endocrine therapy in breast cancer. Endocr Relat Cancer 2003;10:375-88.
67. Schmidberger H, Hermann RM, Hess CF, et al. Combination of anti-estrogenic therapy with radiation in breast cancer: simultaneous or sequential treatment? Onkologie 2005;28:275-80.
68. Shou J, Massarweh S, Osborne CK, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004;96:926-35.
69. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;351:1451-67.
70. Taylor ME, Perez CA, Halverson KJ, et al. Factors influencing cosmetic results after conservation therapy for breast cancer. Int J Radiat Oncol Biol Phys 1995;31:753-64.
71. Turner S, A Sherrat J, Cameron D. Tamoxifen treatment failure in cancer and the nonlinear dynamics of TGFbeta. J Theor Biol 2004;229:101-11.
72. Villalobos M, Aranda M, Nunez MI, et al. Interaction between ionizing radiation, estrogens and antiestrogens in the modification of tumor microenvironment in estrogen dependent multicellular spheroids. Acta Oncol 1995;34:413-7.
73. Villalobos M, Becerra D, Nunez MI, et al. Radiosensitivity of human breast cancer cell lines of different hormonal responsiveness. Modulatory effects of oestradiol. Int J Radiat Biol 1996;70:161-9.
74. Vrieling C, Collette L, Bartelink E, et al. Validation of the methods of cosmetic assessment after breast-conserving therapy in the EORTC "boost versus no boost" trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. European Organization for Research and Treatment of Cancer. Int J Radiat Oncol Biol Phys 1999;45:667-76.
75. Wazer DE, Morr J, Erban JK, et al. The effects of postradiation treatment with tamoxifen on local control and cosmetic outcome in the conservatively treated breast. Cancer 1997;80:732-40.
76. Wazer DE, Tercilla OF, Lin PS, et al. Modulation in the radiosensitivity of MCF-7 human breast carcinoma cells by 17B-estradiol and tamoxifen. Br J Radiol 1989;62:1079-83.
77. Wennberg B, Gagliardi G, Sundbom L, et al. Early response of lung in breast cancer irradiation: radiologic density changes measured by CT and symptomatic radiation pneumonitis. Int J Radiat Oncol Biol Phys 2002;52:1196-206.